MAP3K7 and ovarian cancer: To examine whether TAK1 alters AMPK activity, ovarian cancer cells were co-treated with TAK1 inhibitor 5Z-7-Oxozeaenol (5Z-O), and results showed that inhibition of TAK1 activity in a dose-dependent manner of 5Z-O slightly enhanced AMPK phosphorylation in SKOV3 only, while there’s no effect on AMPK phosphorylation in OVCA433 and SKOV3 cells (Fig. 5e).